NO20053051L - Tretthetsreduserende middel. - Google Patents

Tretthetsreduserende middel.

Info

Publication number
NO20053051L
NO20053051L NO20053051A NO20053051A NO20053051L NO 20053051 L NO20053051 L NO 20053051L NO 20053051 A NO20053051 A NO 20053051A NO 20053051 A NO20053051 A NO 20053051A NO 20053051 L NO20053051 L NO 20053051L
Authority
NO
Norway
Prior art keywords
fatigue
composition
reducing agent
reducing
aged
Prior art date
Application number
NO20053051A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053051D0 (no
Inventor
Kenji Fujii
Taizo Kawabe
Kazunori Hosoe
Takayoshi Hidaka
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Publication of NO20053051D0 publication Critical patent/NO20053051D0/no
Publication of NO20053051L publication Critical patent/NO20053051L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO20053051A 2003-01-31 2005-06-21 Tretthetsreduserende middel. NO20053051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003024758 2003-01-31
PCT/JP2004/000366 WO2004066988A1 (ja) 2003-01-31 2004-01-19 疲労改善剤

Publications (2)

Publication Number Publication Date
NO20053051D0 NO20053051D0 (no) 2005-06-21
NO20053051L true NO20053051L (no) 2005-08-31

Family

ID=32820773

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053051A NO20053051L (no) 2003-01-31 2005-06-21 Tretthetsreduserende middel.

Country Status (11)

Country Link
US (1) US8946303B2 (zh)
EP (1) EP1588703B1 (zh)
JP (1) JP4644121B2 (zh)
KR (1) KR100696924B1 (zh)
CN (1) CN1723015A (zh)
AU (1) AU2004208588B2 (zh)
CA (1) CA2511080C (zh)
NO (1) NO20053051L (zh)
RU (1) RU2304432C2 (zh)
TW (1) TWI322008B (zh)
WO (1) WO2004066988A1 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065672A1 (en) * 2004-01-08 2005-07-21 Kaneka Corporation Antiaging composition
US7708990B2 (en) 2004-03-23 2010-05-04 Kaneka Corporation Coenzyme Q compositions persisting in blood
KR20060130759A (ko) * 2004-03-23 2006-12-19 가부시키가이샤 가네카 혈중 지속성 보효소 ｑ 조성물
TW200603786A (en) * 2004-05-11 2006-02-01 Kaneka Corp Anti-fatigue composition
US20080254016A1 (en) * 2005-03-29 2008-10-16 Kaneka Corporation Composition For Increasing Anti-Oxidation Activity In Blood
US20090226408A1 (en) * 2005-06-24 2009-09-10 Kaneka Corporation Anti-fatigue composition
JP5023253B2 (ja) * 2005-09-14 2012-09-12 株式会社ノエビア 疲労感、倦怠感の予防及び治療用組成物
JP5103374B2 (ja) * 2006-03-13 2012-12-19 株式会社カネカ 心機能不良改善剤または心機能維持剤
US10583098B2 (en) * 2006-05-02 2020-03-10 Sung Lan Hsia Topical co-enzyme Q10 formulations and treatment of pain, fatigue and wounds
WO2008007728A1 (fr) * 2006-07-13 2008-01-17 Kaneka Corporation Préparation orale contenue dans une structure à membrane lipidique, et agent contre la fatigue comprenant une coenzyme comme ingrédient actif
JP2008239528A (ja) * 2007-03-26 2008-10-09 Lion Corp 目及び脳機能改善剤
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
JP5283359B2 (ja) * 2007-08-30 2013-09-04 株式会社カネカ 還元型補酵素ｑ含有組成物
JP5558823B2 (ja) * 2007-10-05 2014-07-23 株式会社カネカ 還元型補酵素ｑ１０の製造方法
IL188681A0 (en) 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
JPWO2009136587A1 (ja) * 2008-05-08 2011-09-08 株式会社カネカ 抗疲労組成物
NZ705666A (en) * 2009-01-23 2016-06-24 Wyeth Llc A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
US9040747B2 (en) 2009-10-16 2015-05-26 Kaneka Corporation Method for producing reduced coenzyme Q10, method for stabilizing same, and composition comprising same
US8865660B2 (en) 2010-12-10 2014-10-21 Broady Health Sciences, Llc Method of treating neurogenic overactive bladder in a mammal or method of treating non-psychological stress-related bladder dysfunction in a female mammal by administering at least on jasmonate
JP6024942B2 (ja) * 2012-02-29 2016-11-16 株式会社福山こめ酢 テストステロン分泌促進剤、抗疲労剤及びその製造方法と利用
CN103371317A (zh) * 2012-04-25 2013-10-30 山东邦奥创业生物科技有限公司 一种核糖功能食品
WO2014153285A1 (en) * 2013-03-16 2014-09-25 Sinatra Stephen T Equine supplement
RU2540476C1 (ru) * 2014-03-27 2015-02-10 Федеральное государственное унитарное предприятие "Государственный ордена Трудового Красного Знамени научно-исследовательский институт химии и технологии элементоорганических соединений" (ФГУП "ГНИИХТЭОС") Повышение работоспособности
JP2018527406A (ja) * 2015-08-11 2018-09-20 アカール ファーマ ピーティーワイ リミテッドＡｋａａｌ Ｐｈａｒｍａ Ｐｔｙ Ｌｔｄ Ｓ１ｐ受容体モジュレーターを含む組成物
CN107007606B (zh) * 2016-02-04 2021-10-26 南京舒鹏生物科技有限公司 一种用于干燥综合症预防及治疗的药物及其组合
CN106177925A (zh) * 2016-08-25 2016-12-07 明光市昊昊蜂业有限公司 一种蜂王浆美容保健品
JP6252922B2 (ja) * 2016-09-27 2017-12-27 ビーエイチエヌ株式会社 テストステロン分泌促進剤、抗疲労剤及びその製造方法と利用
CN106617030A (zh) * 2016-12-12 2017-05-10 钦州学院 一种体力恢复剂及其制备方法
US11419830B2 (en) 2017-05-17 2022-08-23 Berg Llc Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa
US11471426B2 (en) 2019-10-16 2022-10-18 American River Nutrition, Llc Compositions comprising quinone and/or quinol and methods of preparations and use thereof
CN110801018A (zh) * 2019-11-08 2020-02-18 广东医科大学 辅酶q10维生素c运动含片

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938204B2 (ja) 1976-02-14 1984-09-14 エーザイ株式会社 再生不良性貧血治療剤
JPS5942649B2 (ja) * 1976-02-14 1984-10-16 エーザイ株式会社 重症筋無力症治療剤
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
JPH07330584A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd 疲労改善剤
JPH07330593A (ja) * 1994-06-09 1995-12-19 Taisho Pharmaceut Co Ltd 疲労改善剤
JPH1053520A (ja) * 1996-06-03 1998-02-24 Takeda Chem Ind Ltd 抗疲労剤
JP3889481B2 (ja) * 1996-08-16 2007-03-07 株式会社カネカ 医薬組成物
AU739353B2 (en) * 1997-03-27 2001-10-11 Medifoods Inc. Nutritional composition for improvements in cell energetics
JPH10287560A (ja) * 1997-04-11 1998-10-27 Taisho Pharmaceut Co Ltd 医薬組成物
DE19806947A1 (de) * 1998-02-19 1999-08-26 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus mindestens einer Substanz gewählt aus der Gruppe, bestehend aus Carnitin und den Acylcarnitinen, und mindestens einem Chinon und oder mindestens einem Hydrochinon sowie Zubereitungen mit einem Gehalt an solchen Wirkstoffkombinationen
WO2000057871A2 (en) * 1999-03-30 2000-10-05 Purdue Research Foundation Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
WO2001032040A1 (en) 1999-11-01 2001-05-10 University Of Massachusetts Method for selective delivery of lipid-soluble antioxidants into the polar lipid fraction of a food product
EP1231886A4 (en) * 1999-11-24 2005-10-12 Access Business Group Int Llc COMPOSITION FOR THE SKIN SURFACE
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
CA2406570C (en) 2000-05-09 2011-07-12 Kaneka Corporation Dermal compositions containing coenzyme q as the active ingredient
ZA200109677B (en) * 2000-09-06 2002-06-25 Technikon Pretoria A nutritional and pharmaceutical composition.
JP2002363073A (ja) 2001-05-09 2002-12-18 Crescendo Corporation スポーツパフォーマンス
WO2002092067A1 (fr) * 2001-05-10 2002-11-21 Kaneka Corporation Composition pour administration transmucosale contenant une coenzyme q en tant qu'ingredient actif
JP2003119127A (ja) 2001-10-10 2003-04-23 Kanegafuchi Chem Ind Co Ltd 安定な還元型補酵素ｑ製剤
TWI329513B (en) * 2001-10-12 2010-09-01 Kaneka Corp Use of reduced coenzyme q for lessening oxidative stress

Also Published As

Publication number Publication date
CA2511080C (en) 2015-10-13
NO20053051D0 (no) 2005-06-21
KR20050092128A (ko) 2005-09-20
AU2004208588B2 (en) 2009-05-07
US8946303B2 (en) 2015-02-03
RU2005122409A (ru) 2006-01-20
EP1588703B1 (en) 2016-04-20
RU2304432C2 (ru) 2007-08-20
WO2004066988A1 (ja) 2004-08-12
AU2004208588A1 (en) 2004-08-12
CA2511080A1 (en) 2004-08-12
JPWO2004066988A1 (ja) 2006-05-18
AU2004208588A2 (en) 2004-08-12
EP1588703A1 (en) 2005-10-26
US20060165672A1 (en) 2006-07-27
TWI322008B (en) 2010-03-21
TW200501936A (en) 2005-01-16
JP4644121B2 (ja) 2011-03-02
CN1723015A (zh) 2006-01-18
KR100696924B1 (ko) 2007-03-20
EP1588703A4 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
NO20053051L (no) Tretthetsreduserende middel.
CY1107452T1 (el) Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
DK1898876T3 (da) Mucoadhæsive xyloglucanholdige fprmuleringer anvendelige i medicinske anordninger og i farmaceutiske former
WO2002044187A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
ATE434639T1 (de) Wässrige dispersionen von silikon-polyether- blockcopolymeren
NO20044658L (no) Anvendelse av osteoprotegerin til behandling og/eller forhindring av fibrotiske sykdommer
ATE537828T1 (de) Psychotropes mittel und nahrungsmittel zur förderung der gesundheit enthaltend neferin
IS7535A (is) Lyfjablanda
NO20064964L (no) Behandling av svekket respiratorisk funksjon
NO20010833L (no) Orale mukoadhesive sammensetninger inneholdende gastrointestinale aktive bestanddeler
HK1110207A1 (en) Ophthalmic compositions and methods of using the same
WO2005018605A3 (en) Novel formulation of ropinirole
NO20080725L (no) Konserverende sammensetning for oftalmisk anvendelse
ATE324112T1 (de) Topische behandlung bei der mastalgie
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
NO20065471L (no) Anvendelse av IL-6 for behandling eller forebygging av kjemoterapiindusert nevropati.
WO2005089489A3 (en) Use of relaxin to increase arterial compliance
Stenberg et al. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia–a path model investigation
DE602006021321D1 (de) Stabilisierte und konservierte ketotifen enthaltende ophthalmologische zusammensetzungen
ATE440601T1 (de) Hydroxypyridinone zur lokalen behandlung von hautmikrozirulationsstírungen
AR033413A1 (es) Metodo de terapia de reemplazo hormonal y forma de administracion del mismo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application